Rezpegaldesleukin
Moderate-To-Severe Atopic Dermatitis
Phase III
Recruiting
A Phase 3 Study of Rezpegaldesleukin (NKTR-358) for Patients ≥ 12 Years of Age With Moderate-to-Severe Atopic Dermatitis
Jul 02, 2026
―
Rezpegaldesleukin
Alopecia Areata
Phase II
Active Not Recruiting
A Phase 2b Study to Evaluate Rezpegaldesleukin (Rezpeg) in the Treatment of Severe to Very Severe Alopecia Areata in Adult Patients (Rezolve AA)
Mar 25, 2024
―
Rezpegaldesleukin
Moderate To Severe Atopic Dermatitis
Phase II
Active Not Recruiting
A Phase 2b Study to Evaluate Rezpegaldesleukin (Rezpeg) in the Treatment of Adult Patients With Moderate-to-Severe Atopic Dermatitis
Nov 13, 2023
―
C-Til051
Metastatic Non Small Cell Lung Cancer
Phase I
Recruiting
C-TIL051 in Non-Small Cell Lung Cancer
Dec 07, 2022
―
Nktr-255 At 1.5 Μg/Kg, Nktr-255 At 3.0 Μg/Kg, Nktr-255 At 3.0/6.0 Μg/Kg
Non-Hodgkin Lymphoma, Relapsed/Refractory Diffuse Large B-Cell Lymphoma
Phase II/III
Terminated
NKTR-255 vs Placebo Following CD19-directed CAR-T Therapy in Patients With Relapsed/Refractory Large B-cell Lymphoma
Dec 01, 2022
―
Levocetirizine, Ly3471851
Healthy
Phase I
Completed
A Phase I Study of LY3471851 in Healthy Participants
Oct 03, 2022
―
Ly3471851
Healthy
Phase I
Completed
A Single-Dose Study of LY3471851 in Healthy Participants
Aug 09, 2021
―
Pembrolizumab, Bempegaldesleukin
Metastatic Head And Neck Cancer, Recurrent Head And Neck Cancer
Phase II/III
Terminated
BEMPEG With Pembrolizumab vs Pembrolizumab Alone in Patients With Metastatic or Recurrent HNSCC (PROPEL-36)
Jul 09, 2021
―
Nivolumab, Nktr-214
Rhabdomyosarcoma, Ependymoma, Ewing Sarcoma, High-Grade Glioma, Leukemia And Lymphoma, Medulloblastoma, Miscellaneous Brain Tumors, Miscellaneous Solid Tumors, Relapsed, Refractory Malignant Neoplasms, Neuroblastoma
Phase I/II
Terminated
A Study of Bempegaldesleukin (BEMPEG: NKTR-214) in Combination With Nivolumab in Children, Adolescents and Young Adults With Recurrent or Treatment-resistant Cancer
Jan 26, 2021
―
FAQ
What are the FDA phases for drug approval?
The FDA approval process for new drugs is divided into several phases:
a. Preclinical testing
b. Phase 1 – Safety and dosage
c. Phase 2 – Effectiveness and side effects
d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments
e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
a. Preclinical testing
b. Phase 1 – Safety and dosage
c. Phase 2 – Effectiveness and side effects
d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments
e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
What is a clinical trial?
A clinical trial is a carefully designed study in which researchers test a drug, treatment, or medical device in people to evaluate its safety, effectiveness, and potential side effects. These trials are essential for determining whether a new treatment should be approved for widespread use.
What drugs does Nektar Therapeutics (ITH0) have in its pipeline
ITH0 is currently developing the following drugs: Rezpegaldesleukin, Rezpegaldesleukin, Rezpegaldesleukin. These drug candidates are in various stages of clinical development as the company works toward FDA approval.